悦康药业预计2025年净亏损2.35亿—2.8亿元

Core Viewpoint - Yuyuan Pharmaceutical is forecasting a net loss attributable to shareholders of the parent company for 2025, ranging from 235 million to 280 million yuan, indicating a decline compared to the previous year [1] Financial Performance - The expected net loss, excluding non-recurring gains and losses, is projected to be between 260 million and 305 million yuan [1] - The anticipated financial downturn is attributed to adjustments in pricing and sales strategies for the product "Ginkgo Leaf Extract Injection" at the end of 2024 [1] R&D Expenses - The increase in research and development expenses year-on-year is expected to have a significant impact on net profit [1]